当前位置: X-MOL 学术BMJ › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Seven days in medicine: 11-17 July.
The BMJ ( IF 105.7 ) Pub Date : 2018-07-19 , DOI: 10.1136/bmj.k3137
British Medical Journal Publishing Group

The UK National Institute for Health and Clinical Excellence recommended dinutuximab beta (Qarziba) for treatment of high risk neuroblastoma, after an agreement with the company EUSA Pharma to offer the NHS a discount on the average list price of £152 200 (€172 300; $201 400). The rare cancer mainly affects children and adolescents. Dinutuximab beta will be given to those who have at least partly responded to first stage chemotherapy followed by myeloablative therapy and stem cell transplantation. The potential survival gain is substantial, although uncertainty remains about the drug’s long term benefits, said NICE (https://www.nice.org.uk/guidance/gid-ta10069/documents/final-appraisal-determination-document).
Benralizumab (marketed as Fasenra by AstraZeneca) should be an option for people with severe eosinophilic asthma whose symptoms are not adequately controlled with standard treatments, NICE said in draft guidance. The drug is cost effective for people who have had at least three exacerbations in the past year and who have a blood eosinophil count of ≥400 cells/μL and when the biological treatment mepolizumab is not appropriate. AstraZeneca agreed a discount on the list price of £1955 for a 30 mg prefilled syringe.
All patients with a brain tumour who could benefit from 5-aminolevulinic acid (5-ALA) before surgery should have it, NICE said. The dye, known as the pink drink, shows tumour cells glowing pink under …


中文翻译:

服药7天:7月11日至17日。

在与EUSA Pharma公司达成协议后,英国国家健康与临床卓越研究所推荐使用dinutuximab beta(Qarziba)治疗高危神经母细胞瘤,该公司同意为NHS提供平均价152,200英镑(172,300欧元)的折扣。 201 400美元)。罕见的癌症主要影响儿童和青少年。Dinutuximab beta适用于那些对第一阶段化疗,随后的清髓性治疗和干细胞移植至少有部分反应的患者。NICE(https://www.nice.org.uk/guidance/gid-ta10069/documents/final-appraisal-determination-document)表示,尽管仍不确定该药物的长期益处,但潜在的生存收益是可观的。
NICE在指南草案中说,贝那利珠单抗(阿斯利康销售,Fasenra公司销售)应该是严重嗜酸性粒细胞性哮喘患者的选择,这些患者的症状不能通过标准疗法得到充分控制。对于在过去一年中至少发作过三次且血液中嗜酸性粒细胞计数≥400细胞/μL且不宜采用生物治疗美泊珠单抗的患者,该药物具有成本效益。阿斯利康(AstraZeneca)同意对30毫克预填充注射器的标价1955英镑打折。
NICE说,所有脑瘤患者在手术前都可以从5-氨基乙酰丙酸(5-ALA)中获益。这种染料被称为粉红色饮料,在………………的作用下,肿瘤细胞会发出粉红色的光。
更新日期:2018-07-20
down
wechat
bug